Last $13.19 USD
Change Today +0.055 / 0.42%
Volume 3.2M
BSX On Other Exchanges
New York
As of 3:56 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $14.08
52 Week Low
10/16/14 - $11.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation(NYSE:BSX) added to S&P 500 Value Index

Boston Scientific Corporation(NYSE:BSX) added to S&P 500 Value Index

West Virginia Jury Awards $18.5 Million to Plaintiffs in the Latest Boston Scientific Vaginal Mesh Trial

Legal-Bay LLC reported that a West Virginia jury has awarded $18.5 million to plaintiffs in the latest Boston Scientific vaginal mesh trial. The four women plaintiffs involved were all implanted with the Obtryx mesh, a mid-urethral sling which is used to treat incontinence, and they alleged that the implanted device left them with nerve damage, infections, and pain during sexual intercourse. This case against Boston Scientific Corporation was the second federal case filed in multidistrict litigation over their pelvic mesh, and the third case since September in which plaintiffs were awarded damages.

Boston Scientific to Face $5 Billion Court Battle over 2006 Acquisition

Boston Scientific will go to trial on November 20, 2014 facing a potential $5 billion lawsuit for a 2006 acquisition that is widely credited with causing years of headaches for the firm. The firm will appear in court before a federal judge in New York on November 20 to answer to a lawsuit by rival Johnson & Johnson. The New Jersey life sciences giant lost a bidding war nearly a decade ago to buy the pacemaker company Guidant. Boston Scientific paid $27 billion for that company in a deal that is often cited as the beginning of years of debt and resulting financial declines. While the company has been on a rebound for the past year, its growth has stalled as it faces lawsuits not only from J&J, but from patients implanted with a mesh device which many say has caused health problems in thousands of women.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.18 USD +0.05

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $139.35 USD -0.55
CR Bard Inc $168.34 USD -0.76
Olympus Corp ¥4,425 JPY -30.00
St Jude Medical Inc $66.45 USD -0.22
Terumo Corp ¥2,830 JPY -12.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings 61.2x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 24.2x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at